KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Assets (2016 - 2025)

Neogenomics (NEO) has disclosed Assets for 16 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets fell 16.98% year-over-year to $1.4 billion, compared with a TTM value of $1.4 billion through Dec 2025, down 16.98%, and an annual FY2025 reading of $1.4 billion, down 16.98% over the prior year.
  • Assets was $1.4 billion for Q4 2025 at Neogenomics, down from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $1.9 billion in Q3 2021 and bottomed at $1.4 billion in Q4 2025.
  • Average Assets over 5 years is $1.7 billion, with a median of $1.7 billion recorded in 2023.
  • The sharpest move saw Assets surged 7379.11% in 2021, then decreased 16.98% in 2025.
  • Year by year, Assets stood at $1.9 billion in 2021, then fell by 6.94% to $1.7 billion in 2022, then decreased by 3.38% to $1.7 billion in 2023, then dropped by 2.57% to $1.6 billion in 2024, then fell by 16.98% to $1.4 billion in 2025.
  • Business Quant data shows Assets for NEO at $1.4 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.4 billion in Q2 2025.